Palovarotene - Clementia Pharmaceuticals

Drug Profile

Palovarotene - Clementia Pharmaceuticals

Alternative Names: Clm-001; R-667; RAR-gamma; RG-667; RO-3300074

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Eye disorder therapies; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva; Bone disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibrodysplasia ossificans progressiva
  • Phase II Bone disorders
  • Phase I Dry eyes
  • Discontinued Emphysema

Most Recent Events

  • 23 Oct 2018 Clementia Pharmaceuticals announces intention to submit NDA to US FDA for Fibrodysplasia ossificans progressiva in second half of 2019
  • 02 Oct 2018 Phase-I clinical trials in Dry eyes (In volunteers) (Ophthalmic)
  • 02 Oct 2018 Clementia Pharmaceuticals plans a phase I proof of concept trial for Dry eyes (Ophthalmic), in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top